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A TMEFF2-regulated cell cycle derived gene
signature is prognostic of recurrence risk in
prostate cancer
Constantin Georgescu1†, Joshua M. Corbin2†, Sandra Thibivilliers3,7†, Zachary D. Webb2, Yan D. Zhao4, Jan Koster5,
Kar-Ming Fung2,3, Adam S. Asch3,6, Jonathan D. Wren1 and Maria J. Ruiz-Echevarría2,3,6*

Abstract
Background: The clinical behavior of prostate cancer (PCa) is variable, and while the majority of cases remain
indolent, 10% of patients progress to deadly forms of the disease. Current clinical predictors used at the time of
diagnosis have limitations to accurately establish progression risk. Here we describe the development of a tumor
suppressor regulated, cell-cycle gene expression based prognostic signature for PCa, and validate its independent
contribution to risk stratification in several radical prostatectomy (RP) patient cohorts.
Methods: We used RNA interference experiments in PCa cell lines to identify a gene expression based gene
signature associated with Tmeff2, an androgen regulated, tumor suppressor gene whose expression shows remarkable
heterogeneity in PCa. Gene expression was confirmed by qRT-PCR. Correlation of the signature with disease outcome
(time to recurrence) was retrospectively evaluated in four geographically different cohorts of patients that underwent
RP (834 samples), using multivariate logistical regression analysis. Multivariate analyses were adjusted for standard
clinicopathological variables. Performance of the signature was compared to previously described gene expression
based signatures using the SigCheck software.
Results: Low levels of TMEFF2 mRNA significantly (p < 0.0001) correlated with reduced disease-free survival (DFS) in
patients from the Memorial Sloan Kettering Cancer Center (MSKCC) dataset. We identified a panel of 11 TMEFF2
regulated cell cycle related genes (TMCC11), with strong prognostic value. TMCC11 expression was significantly
associated with time to recurrence after prostatectomy in four geographically different patient cohorts (2.9 ≤ HR ≥ 4.1;
p ≤ 0.002), served as an independent indicator of poor prognosis in the four RP cohorts (1.96 ≤ HR ≥ 4.28; p ≤ 0.032)
and improved the prognostic value of standard clinicopathological markers. The prognostic ability of TMCC11 panel
exceeded previously published oncogenic gene signatures (p = 0.00017).
Conclusions: This study provides evidence that the TMCC11 gene signature is a robust independent prognostic
marker for PCa, reveals the value of using highly heterogeneously expressed genes, like Tmeff2, as guides to discover
prognostic indicators, and suggests the possibility that low Tmeff2 expression marks a distinct subclass of PCa.
Keywords: Prostate cancer, Prognostic markers, Cell cycle genes, Risk stratification, TMEFF2
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Background
Cancer of the prostate (PCa) is the second leading cause of
cancer death in male Americans. The clinical behavior of
PCa is variable, and while the majority of PCa cases remain
indolent, 10% of patients progress with aggressive metastatic
disease and subsequent emergence of therapy-resistant PCa
[1, 2]. In current practice, clinical variables including Gleason score, tumor stage, and PSA levels are used at the time
of diagnosis to predict disease outcome [3, 4]. However,
these prognostic factors have limitations, resulting in significant rates of overtreatment, with associated comorbidities
[5–7], and undertreatment, leading to disease progression
and increased risk of PCa-specific mortality [8–10].
The clinical heterogeneity of PCa reflects, in part, a remarkable genomic heterogeneity [11–18]. This suggests
that disease stratification based on molecular features may
be of prognostic value beyond standard clinicopathological
variables, and aid in the clinical management of the disease, as is the case for other cancers, i.e. breast [19–21].
Currently, several tissue-based molecular tests offer prognostic information for patients with PCa either before or
after treatment. These are based on general features of malignancy, such as the Prolaris test (initially described by
Cuzick et al. [22]), which incorporates information from 31
cell-cycle related genes, or on molecular features more specific for PCa (Decipher, Oncotype DX, ProMark, and ConfirmMDx tests [23–27]). In addition, recent work has
outlined the existence of several molecular subtypes of
PCa [28–31]. Notably, in one of these studies, the molecular subtypes were defined by specific driver mutations or
gene fusions that are essentially mutually exclusive and that
are able to categorize up to 74% of the analyzed tumors
[32]. If shown to correlate with clinical behavior, these molecular subtypes could prove critical for the management
and treatment of the disease. However, currently their
prognostic value is not fully established, and a significant
fraction of primary prostate cancers in the study could not
be categorized within these molecular subsets, suggesting
the existence of additional relevant molecular alterations.
High levels of variability in gene expression between tumors can be useful in identifying prostate and other cancers’
risk genes [33]. We hypothesized that molecular subtypes of
primary prostate cancers may exist that have gene expression patterns associated with changes in the expression of
these highly variable genes. A recent report lists TMEFF2 as
one of the top 100 mRNA transcripts with the highest levels
of inter-tumor variability in primary PCa tissues [34].
TMEFF2 is an androgen regulated transmembrane protein
mainly restricted to brain and prostate. Our studies in PCa
demonstrate a role of TMEFF2 as a tumor suppressor [35–
38]. Furthermore, studies using limited numbers of clinical
samples, reveal changes in the expression of Tmeff2 with
disease stage in PCa [39, 40] and gliomas [41], supporting
an important role of Tmeff2 in these diseases.
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We have investigated the expression pattern of TMEFF2
in human prostate tissues and explored the potential of a
TMEFF2 associated gene signature as a biomarker for disease prognosis. We report that low TMEFF2 mRNA expression is associated with decreased disease free survival
(DFS) in the MSKCC PCa dataset. Using transcriptional
profiling of cell lines and publically available PCa clinical
data, we have identified a low TMEFF2 driven gene signature associated with poor clinical outcome, comprised of
cell cycle related genes. This study not only provides new
insights into the clinical relevance of Tmeff2 in cancer, but
also specifies a group of cell cycle related genes as prognostic and potential therapeutic targets.

Methods
TMEFF2 expression data

TMEFF2 mRNA expression in benign and malignant samples of PCa was interrogated using Oncomine Compendium of Expression Array data [42] in the following
cohorts: Varambally et al. (n = 19; GSE3325; [43]), Vanaja
et al. (n = 40; [44]), Grasso et al. (n = 122; GSE35988; [45]),
and Taylor et al. (or MSKCC; n = 185; GSE21032; [46]).
Validation cohorts

Four prostate cancer cohorts were used in this study to establish the prognostic value of the TMCC11 signature:
MSKCC [46] (GSE21032); Cambridge [34] (GSE70768)
and Stockholm [34] (GSE70769), are microarray datasets,
and the TCGA PRAD (https://gdc.cancer.gov), a RNA
sequencing cohort. Cancer samples for all cohorts were
from RP specimens. Biochemical recurrence (MSCKK,
Cambridge and Stockholm) or recurrence/progression
(TCGA-PRAD) was the follow-up endpoint. Clinical,
histopathological data and summary of the cohorts are
listed in Table 1 and Additional file 1: Table S1.
Mammalian cell culture and treatment

The LNCaP and 22Rv1 cell lines were purchased from
American Type Culture Collection (ATCC; Manassas,
VA) and cultured as recommended. Dihydrotestosterone
(DHT; Sigma, Burlington,MA) was used at a concentration of 10 nM. For TMEFF2 knockdown, LNCaP and
22Rv1 cells were transduced with pLKO.1 lentiviral vectors with antisense TMEFF2 sequences shTMEFF2–0
(TRCN0000073518), shTMEFF2–1 (TRCN0000073519)
and shTMEFF2–2 (TRCN0000073521). See Additional
file 1: Table S7 for sequences.
RNA extraction and RNA-Seq

LNCaP cell expressing sh_TMEFF2 or the sh_scramble
control were grown for 14 days after transduction and
then 24 h in hormone-depleted media before stimulation
with 10 nM DHT (or ethanol as vehicle control) for 24 h
prior to harvesting for RNA extraction. Three biological
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Table 1 Clinical and pathological characteristics of the prostate cancer datasets used in this study
MSKCC
(Taylor et al.)
n = 140

Cambridge
(Ross-Adams et al.)
n = 112

Stockholm
(Ross-Adams et al.)
n = 92

TCGA-PRAD
(TCGA)
n = 490

Age (years)
Mean

58.04

62

61

Range

37.3–83.0

41–73

41–78

6.15

7.9

PSA
Median

7.95

< 10

104

80

56

≥ 10

34

31

34

Unknown

2

1

2

Biopsy Gleason
≤3+4

128

77

68

≥4+3

12

27

22

8

2

Unknown
Surgical Gleason
≤3+4

94

83

56

197

≥4+3

44

29

34

293

Unknown

2

2

Extra-capsular ext.

(mri + ct scan combined)

Y

97

77

42

31

N

43

35

48

199

2

260

NA/equivocal
Positive surgical margins
Y

33

26

42

165

N

107

86

50

311

Unknown

14

Recurrence
Y

36

19

45

91

N

104

93

47

399

pT2a-c

87

35

47

184

pT3a-c

46

77

42

290

pT4

7

3

10

Pathology Stage

Unknown

6

The table defines the characteristics of the samples used in this study for each of the datasets

replicates per sample were used. Total RNA was extracted
with RNeasy mini kit (Qiagen, Waltham, MA) and cDNA
was synthesized with SuperScript III First-Strand synthesis
system (Life Technologies Inc., Carlsbad, CA). RNA integrity and quantity was assessed using the Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA). Raw 75 bp
paired-end sequences were generated from an Illumina
NextSeq 500 sequencer (Illumina, San Diego, CA). Sequenced reads first underwent quality control with the
FASTQC tool and then aligned to a contaminant genome
to filter out reads which align to human ribosomal RNA,

poly-A, poly-C, phiX virus or mitochondrial DNA sequence. The filtered reads were trimmed using Trimmomatic [47], as well as read clipping based on quality over a
sliding window, retaining reads with a minimum length of
15 bp. Trimmed, filtered reads were pseudoaligned to the
GRCh38 human reference transcriptome using kallisto
version 0.42.3 [48], with enabled bias correction and 50
bootstrapping rounds. Expression values for 173,259
unique transcripts were measured and transcripts with an
average of 5 count per million (CPM) or less across all
samples were removed from further analysis. To perform
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differential expression analysis (LNCaP-sh_TMEFF2 vs.
LNCaP-sh_scramble control), CPM values were summarized at the gene level and normalized with the R packages
[49] and DESeq2 [50] to identify significantly differentially
expressed genes (DEGs) with fold change ≥1.5 and
FDR-adjusted p-value ≤0.05. Data deposited in NCBI
GEO under accession number GSE117180.
Real-time polymerase chain reaction (RT-PCR)

Total RNA was extracted with RNeasy mini kit and cDNA
was synthesized with iScript™ Reverse Transcription
Supermix for RT-qPCR (BioRad, Hercules, CA). Quantitative RT-PCR was performed using the SsoAdvanced™
Universal SYBR® Green and gene specific primers
(Additional file 1: Table S7) on the Biorad CFX96™ Touch
Real-Time PCR Detection System (BioRad, Hercules, CA).
All RT-PCR experiments were performed under MIQE
guidelines, using three biological replicates and two technical replicates.
Western blotting

Cell lysates were prepared in RIPA buffer containing a
protease inhibitor mixture and analyzed by Western blot
as described before [38], using the following antibodies:
TMEFF2 (HPA015587, Sigma) at a 1:1000 dilution; AR
(sc-7305, Santa Cruz Biotechnology Inc., Dallas, TX) at a
1:1000 dilution; and Calnexin (ab22595; Abcam, San
Francisco, CA) at a dilution of 1:4000.
TMCC11 signature selection process

From the initial group of 25 genes nuclear genes selected
as significantly upregulated (Log2 fold change ≥1.8, ≤3.1;
FDR < 0.05) by DHT in the LNCaP-TMEFF2 knockdown
cells, we chose the 21 top-ranking upregulated genes
(Log2 fold change ≥2.0) (Additional file 1: Figure S3).
We interrogated this 21 gene subset in the MSKCC
dataset (n = 150) in cBioPortal [51, 52] and selected
those genes (n = 11; TMCC11) whose expression was
upregulated in at least 4 of those patients with low
TMEFF2 mRNA expression, and that maintain a strong
functional association as demonstrated using STRING
[53] and IPA pathway analyses (Additional file 1: Figure S4).
Two other signatures were used for SigCheck analysis.
TMCC13 is a modified TMCC11 signature including two
additional genes, E2F7 and GSG2 (from the TMEFF2 21
top-ranking upregulated genes; Additional file 1: Figure
S3), selected based on their individual prognostic values
and lack of overlap with genes from the Cuzick [22] signature. TMCC3 consist of the CDC45, NCAPG and CLSPN
genes and was selected from TMCC11 as the optimal subset in predicting time to BCR in the Stockholm dataset.
For this purpose, the dependence of time to BCR on the
signature gene expression was modeled using GLM cox
regression, and the search for the best subset relied on
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elastic net regularization, a standard features selection
procedure implemented in the R package glmnet.
TMCC11 signature score development

Patients were divided in two categories (high and low)
based on the TMCC11 gene signature, by calculating the
mean expression over all the genes in the signature for each
sample. The distribution for the population was calculated,
and samples were included in the high group when their
mean fell within the upper tertile (above the 67th percentile) and in the low group when below the 67th percentile.
Databases and statistics

Databases/platform used during this study: cBioportal [51,
52], Oncomine [42], the R2 genomic analysis and
visualization platform (http://r2.amc.nl); the STRING database [53]; and SurvExpress [54]. The parameters used are
referenced in the corresponding figure legends if applicable.
For publicly available microarray or RNA-Seq expression
data sets, the normalized expression data was downloaded
from the Oncomine, cBioportal or R2 databases.
Hierarchical clustering of the TMCC11 signature
genes (Euclidean distance with average linkage on zscore
transformed expression values) on samples from the
MSKCC dataset was performed in R2.
Data analysis were performed by non-parametric
Wilcoxon multiple comparison test or Student t-test as indicated in figure legends. Statistical significance was defined as P < 0.05 unless otherwise stated. Time-to-event
outcomes were evaluated using Kaplan-Meyer analysis
and survival-time differences were compared using the
log-rank test. Uni-, multi-variate and C-statistics were
used to assess the independent effect of biomarker status
on clinical outcome. Univariate hazard ratios and p-values
were obtained using the Cox proportional hazard model.
Multivariate analysis was performed using the Cox proportional hazard model. A stepwise model selection procedure coupled with Cox proportional hazard model was
used to define the final model. The Harrell’s method was
used to compute the concordance statistics. Covariates included in the multivariate models were: biopsy and/or surgical gleason score, PSA, pathological T- stage, positive
surgical margins and/or extracapsular extension. Covariates were adjusted as follow: Gleason – High (≥4 + 3):
Low (≤3 + 4); PSA – High (≥10):Low(< 10); Path Stage –
High(≥T3):Low(≤T2); Positive surgical margins -Y:N;
Extracapsular extension (ECE) – Y:N. These analyses were
conducted using SAS 9.4 and a p-value of less than 0.05
or 0.01 if indicated, was deemed statistically significant.
Gene signature analysis with SigCheck

We analyzed the prognostic potential and specificity of
the TMCC11 signature using the Bioconductor package
SigCheck [55]. This software allows comparison of a
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gene signature prognostic performance against random
and known gene signatures. In a first analysis, we compared the prognostic power of the TMCC11 gene signature and 253 oncogenic signatures available from the
literature. The prognostic power of a gene signature was
quantified by the log-rank test p-value for the difference
between the time to BCR in high versus low risk groups
according to overall signature gene expression. Mean expression over all the genes in the signature for each sample was computed, and high versus low expression was
considered as over or below the 67th percentile respectively. Log-rank P-values for each signature were computed using the Stockholm ( [34], GSE70769),
Cambridge ( [34], GSE70768) and MSKCC ( [46],
GSE21034) datasets downloaded from the GEO website.
In a second analysis, we comparatively assessed the superiority of the TMCC11 and the other 253 oncogenic
signatures against randomly constructed predictors. For
each signature under study, 10,000 signatures of the
same number of genes were selected at random and for
each log-rank p-value scores of their predictive power
were computed as described above. A bootstrap p-value
was then determined as the proportion of random gene
signatures scoring better than the original gene signature. Stockholm, Cambridge and MSKCC datasets were
also used for this analysis. The code for the analysis is
available upon request. See Additonal file 1 for supplementary Methods.

Results
Low expression of TMEFF2 is associated with advanced
disease and is prognostic of clinical outcome

The previously described cell growth inhibitory function
of TMEFF2 in PCa [35–37] led us to determine the relationship of Tmeff2 expression alterations to the clinicopathologic features of PCa. We first analyzed tumor
associated changes in TMEFF2 expression by immunohistochemistry in PCa tissues (Additional file 1: Figure S1A).
TMEFF2 protein expression was higher in patients with
localized disease as compared to non-tumor samples (not
shown). However, when patients were stratified by tumor
stage, TMEFF2 expression was significantly decreased in
more advanced pathological stages (Additional file 1:
Figure S1B).
We then used Oncomine [42] to examine alterations of
TMEFF2 mRNA expression in publically available samples
from PCa patients. Expression of TMEFF2 mRNA is significantly increased in the primary tumors of patients with
PCa when compared to normal tissue, in multiple independent datasets (Fig. 1a). However, in samples from metastases and castration resistant prostate cancer (CRPC),
the levels of TMEFF2 mRNA are either unchanged or decreased compared to normal prostate, and significantly
decreased (P < 0.05) when compared to primary tumors
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(Fig. 1a). These data suggest a negative correlation between TMEFF2 mRNA expression and progression to the
advanced stages of PCa.
Based on these observations, we analyzed the prognostic value of TMEFF2 mRNA expression in the MSKCC
dataset ( [46]; Table 1), a publically available human PCa
dataset with clinical outcome data. Kaplan-Meier analysis demonstrated a significant (p < 0.0001) correlation
between TMEFF2 levels and disease progression
(assessed by biochemical recurrence, BCR). Patients with
the lowest TMEFF2 mRNA expression had faster BCR
(20 vs. 110 months; Fig. 1b). These findings underscore
the clinical significance of Tmeff2 in cancer.
TMEFF2 silencing in the LNCaP cell line increases
androgen-driven expression of a group of cell-cycle
related genes

TMEFF2 is one of the top 100 mRNA transcripts with
the highest levels of inter-tumor variability in patient
samples from several publically available datasets ( [34]
and Additional file 1: Table S1). Such heterogeneity and
the fact that low TMEFF2 mRNA expression correlates
with advanced disease, suggest that it may define a molecular signature with prognostic value. To begin understanding the molecular consequences of decreased
TMEFF2 expression and its potential to define a prognostic gene signature, we conducted TMEFF2-targeted
RNA interference experiments. Using shRNA, we silenced expression of TMEFF2 in LNCaP cells (Fig. 2a
and Additional file 1: Figures S2A and S2B), a PCa cell
line that expresses high levels of TMEFF2 mRNA and
protein. Using RNA-Seq, we identified a group of 25 nuclear genes that were moderately but significantly upregulated by DHT in the context of TMEFF2 silencing
(Log2 fold change ≥1.8, ≤3.1; FDR < 0.05), as compared to
control cells (transduced with scramble shRNA; Additional
file 1: Figure S2C). STRING pathway analysis [53] suggests
that most of these genes are functionally associated
(Additional file 1: Figure S2D) and belong to the DNA replication and cell cycle gene ontology categories. All together these results suggest that TMEFF2 silencing alters
expression of androgen receptor (AR) targets, andthat previously reported TMEFF2 effects on growth [37] may be
driven, in part, by TMEFF2-modulated AR-mediated expression of genes involved in cell cycle related processes
(Additional file 1: Supplementary Discussion).
Out of the initial group of genes, we selected 11 (see
Methods and Additional file 1: Figsure S3A and S3B) referred to as the “TMEFF2 modulated cell cycle 11
(TMCC11)” gene signature. qRT-PCR analysis in LNCaP
cells confirmed that DHT mediated induction of the
TMCC11 genes was significantly increased in LNCaP
cells in which TMEFF2 expression was low compared to
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A

B

Fig. 1 Low expression of TMEFF2 mRNA is associated with advanced disease and clinical outcome. a Scatter plot showing TMEFF2 mRNA expression levels in
normal, primary and metastatic/CRPC tissue from patients from different prostate cancer cohorts. Expression levels were obtained from Oncomine and
compared using a Wilcoxon multiple comparison test. b Kaplan-Meier analysis of biochemical-relapse free survival for patients from the MSKCC prostate cohort
stratified by TMEFF2 mRNA expression (n = 11; lowest expression in the cohort) vs. the rest of the patients. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001

control cells (Fig. 2b). High expression of these genes
with low TMEFF2 expression was also seen in patients’
samples from the MSKCC dataset (Additional file 1: Figure S3C). Clustering analysis of the TMCC11 signature
genes in the MSKCC dataset indicate that expression of
these genes is highly correlated (Fig. 2c). These 11 genes
are all tightly related to cell-cycle and DNA replication
and repair processes (Additional file 1: Figure S3B).
Moreover, silencing of TMEFF2 in PCa cells affects cell

cycle progression (Additional file 1: Figure S4) supporting the role of TMEFF2 in modulating expression of
cell-cycle related genes (see also Additional file 1:
Supplementary Discussion).
In clinical samples from the Grasso [45] and MSKCC
[46] datasets, the expression of the individual genes from
the TMCC11 signature is significantly increased in
CRPC and metastatic disease samples when compared
to normal tissue, and inversely correlated with the
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LNCaP shRNA:
DHT (10nM):

Scramble
−
+

TMEFF2-0
−
+

TMEFF2-1
−
+

TMEFF2-2
−
+

α:TMEFF2
α: Calnexin

B
Fold induction +/- DHT

sh_scramble
2.50
2.00

**

*

*

sh_TMEFF2-2
*

*

**

**

sh_TMEFF2-1
**

*

**

**

**
*

*
**

1.50
1.00
0.50
0.00

C
Biopsy gleason gr.
Clinical stage
Disease status
Pathological stage

Signature 11a

Expression zscores

Biopsy Gleason grade
5

6

7

8

9

Clinical stage
t1c

t2a

t2b

t2c

Signature score

Disease status
t3

t3a

PCa

Pathological stage
t2a

t2b

t2c

t3a

t3b

t3c

t4

Fig. 2 TMEFF2 silencing in PCa cells induces androgen-driven expression of cell cycle genes. a Western Blot analysis to determine knockdown of
TMEFF2 in LNCaP cells using three different TMEFF2 targeted shRNAs. Only sh_TMEFF2–1 and sh_TMEFF2–2 appreciably silenced TMEFF2 expression.
Note that Tmeff2 is an androgen-regulated gene. Representative blot from > 3 repeats. b qRT-PCR data in the LNCaP-sh_TMEFF2 cells confirming
increased expression in response to androgen stimulation of the cell cycle genes selected for the TMCC11 signature. Data is the average of 3
independent repeats and was analyzed using T-test. Error bars correspond to s.e.m. c Clustering analysis of TMCC11 signature genes in the MSKCC
cohort. Each column corresponds to an individual patient. The status of some clinicopathological variables for each sample has been included in the
figure at the top of the heatmap. *P < 0.05; **P < 0.01

expression of TMEFF2 in the same samples (Additional
file 1: Figure S5A and S5B). In addition, mRNA coexpression analysis using the PCa MSKCC and PRAD TCGA
datasets indicates that these genes are significantly
co-expressed (Additional file 1: Figure S6).
The TMEFF2-modulated gene signature is an independent
marker of recurrence after prostatectomy in multiple
clinical datasets

Based on the results suggesting that loss of TMEFF2 often
predates aggressive/metastatic disease, we postulated that
the TMEFF2-modulated TMCC11 gene signature could
have prognostic value. We evaluated this hypothesis using
BCR as the clinical endpoint in the PCa MSKCC dataset

[46] (Table 1 and Additional file 1: Table S2 and Figure S7
provide information on the samples). The MSKCC dataset
includes a number of prostatectomy samples from patients with wide range of times to BCR as measured by increased levels of PSA. Individually, increased expression of
each of the genes comprising TMCC11 was statistically
significant (P < 0.01) in predicting BCR (Additional file 1:
Table S3; for CLSPN p = 0.0137). In Kaplan-Meier analyses, high expression of the TMCC11 signature was associated with a median time to progression of 55.39 months
vs. greater than 150 months for patients with low expression of TMCC11 (log-rank P value = 1.11e-05; Fig. 3a).
These results indicate that the TMCC11 signature is a
powerful predictor of aggressive PCa, segregating the
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A

B

C

D

Fig. 3 High TMCC11 expression correlates with decreased disease-free survival in several independent PCa datasets. Kaplan-Meier analysis of
biochemical-relapse free survival in the MSKCC (a), Cambridge (b), Stockholm (c) and PRAD-TGCA (d) datasets. Patients were divided in two
categories with the upper tertile of the TMCC11 used at the cut point. Red indicates high TMCC11 group

tumors into high and low-risk groups based on time to
BCR. We obtained similar results using the SurvExpress
[54] database for analysis (Additional file 1: Figure S8).
In Cox regression analyses, TMCC11 was a significant
prognostic variable (p < 0.001) with a hazard ratio (HR)
of 4.1 (Table 2). In multivariate analysis, and a model
constructed using a forward stepwise selection process
coupled with Cox proportional hazard, TMCC11
remained a significant prognostic variable with a HR of
2.27 and 2.35 respectively (Table 2). The final model also
selected pathological T-score and surgical Gleason score
as significant predictors of BCR (Table 2).
We validated the prognostic findings in additional independent publically available datasets (see Table 1,
Additional file 1: Table S2 and Fig. S7 for descriptions).
Kaplan-Meier analysis of relapse free survival demonstrated that TMCC11 was a significant (log-rank p =
5.75e-04, p = 1.52e-04 and p = P = 1.01e-07) predictor of
outcome in the Cambridge (CAM; n = 112; [34]),
Stockholm (STO; n = 92; [34]) and PRAD TCGA
(n = 490) cohorts, segregating patients with better/worse

prognosis based on disease recurrence data over 60, 100
and 180 months respectively (Fig. 3b-d). Results using
multivariate Cox regression analysis including expression
level of the TMCC11 signature and several clinical variables, demonstrate that the TMCC11 signature is an independent predictor of recurrence after prostatectomy in
these datasets (Table 2). Taken together, these data suggest
that the TMCC11 signature is prognostic for risk of disease recurrence after radical prostatectomy, and has an
added benefit in the context of standard clinical variables
in several independent datasets.
The prognostic value of the TMCC11 signature was further evident using C-statistics (Additional file 1: Table S4).
The TMCC11 signature was a significant predictor across
all datasets. In the TCGA-PRAD, it performed better
(C-index, 0.64; confidence interval, 0.58–0.70; p < 0.001)
than Gleason (C-index, 0.62; confidence interval,
0.58–0.67; p < 0.001) or pathological score (C-index, 0.61;
confidence interval, 0.57–0.66; p < 0.001). Moreover, in all
the datasets, the TMCC11 signature significantly improved prognostic ability when combined with other
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Table 2 Uni- and multivariate Cox regression analysis of disease recurrence in several PCa datasets
UNIVARIATE ANALYSIS
MSKCC

CAM

STO

TCGA

MULTIVARIATE ANALYSIS

FINAL MODEL

HR (95% CI)

p-value

HR (95% CI)

p-value

HR (95% CI)

p-value

TMCC11

4.10 (2.08, 8.1)

< 0.001

2.27 (1.05,4.91)

0.038

2.35 (1.14,4.87)

0.021

Biop. Gleason

4.26 (1.93, 9.42)

< 0.001

0.96 (0.36,2.59)

0.943

PSA

2.98 (1.53, 5.83)

0.001

1.66 (0.79,3.49)

0.372

Path Stage

4.62 (2.30,9.27)

< 0.001

4.15 (1.56,11.04)

0.459

2.99 (1.42,6.29)

0.004

Surg. margins

2.07 (1.06, 4.06)

0.034

0.90 (0.42,1.95)

0.776

ECE

2.10 (0.92,4.80)

0.79

0.42 (0.12,1.29)

0.415

Surg. Gleason

10.56 (4.87,22.86)

< 0.001

7.92 (3.16,19.87)

< 0.001

6.78 (2.92,15.73)

< 0.001

3.53 (1.31,9.51)

0.013

4.31 (1.70,10.91)

0.002

TMCC11

4.76 (1.80, 12.59)

0.002

4.28 (1.53, 11.99)

0.006

Biop. Gleason

3.25 (1.32, 8.02)

0.011

1.10 (0.25,4.93)

0.897

PSA

1.50 (0.57, 3.95)

0.412

2.82 (1.00,7.98)

0.050

Surg. Gleason

4.68 (1.88,11.63)

< 0.001

5.12 (1.07, 24.55)

0.041

Surg. margins

1.64 (0.62, 4.35)

0.324

2.08 (0.76,5.71)

0.156

ECE

1.82 (0.60,5.48)

0.288

0.85 (0.28,2.64)

0.780

TMCC11

3.00 (1.65,5.44)

< 0.001

2.69 (1.46,6.11)

0.003

2.89 (1.56,5.36)

< 0.001

Preop. Gleason

2.67 (1.44,4.96)

0.002

1.40 (0.66, 2.99)

0.381

2.12 (1.12,4.02)

0.021

3.69 (1.89,7.20)

< 0.001

PSA

1.61 (0.89,2.92)

0.116

1.05 (0.56,1.98)

0.879

Surg. Gleason

3.62 (2.00,6.58)

< 0.001

1.77 (0.84,3.74)

0.136

Surg. margins

1.99 (1.10,3.59)

0.023

1.84 (0.96,3.54)

0.068

ECE

4.21 (2.19,8.09)

<.001

2.98 (1.46,6.11)

0.003

TMCC11

2.94 (1.94, 4.46)

< 0.0001

1.96 (1.26,3.05)

0.003

1.96 (1.26,3.05)

0.003

Gleason

4.08 (2.27, 7.34)

< 0.0001

2.29 (1.20, 4.38)

0.012

2.29 (1.20, 4.38)

0.012

Path Stage

3.68 (2.07, 6.51)

< 0.0001

2.25 (1.22, 4.15)

0.010

2.25 (1.22, 4.15)

0.010

Gleason – High (≥4 + 3): Low (≤3 + 4); PSA – High (≥10):Low(< 10); Path Stage –High(≥T3):Low(≤T2); Positive surgical margins -Y:N; Extracapsular extension (ECE) – Y:N

clinical variables (Additional file 1: Table S4). The persistence of the interaction terms as significant effects proves
that the TMCC11 predictive effectiveness might vary with
the levels of the other clinical variables.
In selected patients from the MSKCC and TCGAPRAD datasets with high pathological T (≥ T3) or
Gleason (≥ 4 + 3) scores, high TMCC11 significantly
stratified men at risk for disease recurrence/progression
(Additional file 1: Figures S9 and S10). TMCC11 provides prognostic information in high-risk patients beyond that provided by established clinicopathological
prognostic features as demonstrated using multivariate
analysis (Additional file 1: Tables in Figures S9 and S10).
These results suggest that TMCC11 has prognostic value
in men with high-grade tumors, after RP. TMCC11
failed to stratify patients with low surgical Gleason score,
however, preliminary data using the MSKCC [46] and
Stockholm [34] datasets indicate that TMCC11 can
stratify patients presenting with low biopsy Gleason
score, suggesting that the signature may be informative
for PCa management after a positive biopsy (Additional
file 1: Figure S11).

Prognostic assessment of the TMCC11 gene signature

Several gene signatures have prognostic capabilities in
PCa. We therefore conducted additional tests to determine the value of the TMCC11 signature when compared
to other signatures, using the Bioconductor package
SigCheck [55]. This software allows comparison of a gene
signature’s prognostic performance against random and
known gene signatures. Initially, we analyzed the prognostic power (based on time to recurrence) of TMCC11 and
other previously identified oncogenic signatures: 6 signatures for PCa [22, 25, 34, 56–58], 189 oncogenic signatures from multiple cancer types in MSigDB, and 48
breast oncogenic signatures (compiled in [59]) (n = 243,
Table 3 and Additional file 1: Table S5). TMCC11 outperformed most signatures (Additional file 1: Table S5).
Considering just the 6 PCa gene signatures, only the
Cuzick (n = 31) signature achieved comparable performance to the TMCC11 across the three datasets for identifying patients with shorter time to biochemical relapse,
and the performance depended on the dataset utilized
(Table 3). Of note, 5 genes within the Cuzick set overlap
with the TMCC11 set. We obtained similar results using
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Table 3 Prognostic potential of PCa signatures
P-values (compared to known PCa signatures)

P-values (compared to random sets of genes)

Dataset Signature

STO

CAM

MSKCC

STO

CAM

MSKCC

Ref

CUZICK

0.00466

0.01610

2.10E-06

0.0182

0.0272

0.0000

22

TMCC11

0.00915

0.00479

0.000173

0.0305

0.0120

0.0018

This study

HES6

0.00544

0.00447

0.24900

0.0242

0.0126

0.5834

56

ROSS(100E)

0.17000

0.00720

0.06070

0.2609

0.0173

0.1388

34

IRSHAD

0.14100

0.04040

0.14500

0.2208

0.0552

0.2819

57

ONCOTYPEDX

0.05380

0.15600

0.20600

0.1126

0.1846

0.3586

25

SHARMA

0.46600

0.29700

0.60400

0.5489

0.3234

0.7237

58

Left columns: Comparative TMCC11 and known PCa signatures prognostic potential. Performance scored by log-rank test p-value of the difference on time to BCR
between high and low risk groups defined by the overall gene expression signature. Right columns: Comparative analysis for TMCC11 and known PCa signatures
over performance against random signatures. For each signature, 10,000 equal size signatures were generated at random and evaluated for predicting early
relapse by log-rank test p-value. An overall bootstrap p-value score was computed as proportion of random signatures performing better than the initial
signature. For both analyses, the data is sorted by first principal component of the individual rankings of the 3 columns corresponding to the Cambridge,
Stockholm and MSKCC datasets. The Ross (100E) signature corresponds to the genes selected based on transcriptome profiling only. See also Additional file 1:
Tables S5 and S6 for a full list with additional signatures

two other TMCC11 derived signatures, TMCC13 and
TMCC3 (Additional file 1: Table S5). TMCC13 is a
modified form of TMCC11 including two additional
genes, E2F7 and GSG2, while TMCC3 consisted of only
3 genes from the TMCC11 signature that do not overlap with the Cuzick signature. These results underscore
the independent prognostic value of the genes included
in the TMCC11 signature.
We then analyzed the performance of the oncogenic signatures against 10,000 signatures consisting of the same
number of genes (for the specified signature) selected at
random (Tables 3 and Additional file 1: Table S6). The
TMCC11 signature performed in the 97th and 99th
percentiles, with only 3, 1.2 and 0.18% of the random
signatures demonstrating an equal or smaller p-value
(empirical p-values of p = 0.0305, p = 0.012 and p = 0.0018)
in predicting relapse in the Stockholm, Cambridge and
MSKCC datasets respectively. Considering the PCa signatures, only the Cuzick (n = 31) signature achieved comparable performance to the TMCC11 across the three
datasets (Table 3). TMCC11, TMCC13 and TMCC3 outperformed most of the oncogenic signatures described
above (n = 243), when tested against random signatures
(Additional file 1: Table S6).

Discussion
Here, we have identified an 11-gene prognostic signature
(TMCC11) for PCa progression consisting of genes associated with cell-cycle and DNA damage response. The prognostic value of this signature was confirmed on several
publically available cohorts totaling 834 samples from
geographically different cohorts of patients that underwent RP. TMCC11 is an independent predictor of biochemical recurrence after RP and added significant
prognostic value to standard clinicopathological variables.
In multivariate analysis TMCC11 was the only variable

consistently predictive of disease recurrence in all of the
datasets, and it significantly increased risk prediction over
other clinical variables and when combined with other
variables (Table 2 and Additional file 1: Table S4).
Moreover, in subsets of patients with high Gleason or
pathological scores, the TMCC11 signature provided a
statistically significant stratification of patients identifying
high and low risk groups for disease recurrence, and preliminary data suggests that TMCC11 can stratify patients
that present with low biopsy or pre-operative Gleason
scores. All together, these results suggest that TMCC11
may provide relevant prognostic information in several
clinical scenarios and have an impact not only on the decision of whether to provide adjuvant therapy after RP, but
also on treatment management after a positive biopsy.
Genomic and transcriptomic analyses have provided
insight into the complexity of prostate tumors and the
existence of molecular subtypes. However, the clinical
applicability of these classifications has been thwarted,
due in part to the highly heterogeneous nature of PCa
and the difficulty of identifying additional relevant alterations that occur at low frequencies [11–18] [60]. We
hypothesized that heterogeneously expressed genes can
expose unidentified molecular subclasses of PCa and/or
identify translationally relevant gene sets. Expression of
Tmeff2, an androgen regulated gene, is highly variable
across several different PCa datasets ( [34], Additional
file 1: Table S1). Low TMEFF2 mRNA expression significantly associated with shorter time to post-RP BCR.
Although the prognostic value of low TMEFF2 mRNA
levels is uncertain, low TMEFF2 mRNA correlates with:
1) increased androgen response of the cell cycle genes
that define the TMCC11 signature in cell lines; and 2)
increased mRNA levels of the same genes in samples
from clinical datasets (see also Additional file 1:
Supplementary Discussion). Interestingly, SPINK1 also
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demonstrates highly variable expression across the same
datasets (Additional file 1: Table S1). SPINK1 is an
androgen-regulated gene highly overexpressed in approximately 10% of PCa cases [61–63]. While the prognostic
role of SPINK1 for PCa is unclear [64], it has been suggested that pathways downstream of SPINK1 may have
translational and prognostic significance [64, 65]. These
observations hint to highly variably expressed genes as a
potential source of information with translational value.
Currently several tissue-based genomic biomarkers
offer prognostic information for patients with PCa either
before or after treatment [23]. The Decipher™ [24],
Oncotype DX® [25] and Prolaris® [22] are commercially
available panels based on measurement of gene expression changes at the RNA level. The Prolaris® panel,
based on the set described in Cuzick [22], examines the
expression of 31 genes involved in cell cycle progression
and 5 out of the 11 genes in TMCC11 are common to
this panel. We observed a similar prognostic performance for the Cuzick [22] and the TMCC11 signatures
when compared against random size-matched signatures. In addition, the prognostic power (based on
p-value) of our signature vs. Cuzick [22] was dependent
on the dataset utilized, but they were similarly informative and both behaved as strong risk predictors. While
these comparisons need to be verified in independent
studies, TMCC11 represents a smaller and more focused
distinct gene set with potentially added value in specific
patient subsets. The smaller size of the TMCC11 signature (11 genes vs. 31 of Cuzick [22]) is an advantage in
clinical use since smaller signatures are more amenable
to testing with reduced RNA quantities (i.e. biopsy samples) or even assayed with immunohistochemistry. In
addition, TMCC3, a signature consisting of three genes
selected from the TMCC11 signature, that does not
overlap with the Cuzick gene set, demonstrated excellent
prognostic ability in SigCheck analysis. This suggests
that subsets of the TMCC11 genes can be of prognostic
value. Finally, the fact that our studies have independently led to the identification of a cell-cycle based signature validates the results and points to the value of using
cell cycle genes as prognostic markers in PCa. See Additonal file 1 for a supplementary Discussion.

Conclusions
Using an unconventional approach, we have identified an
11-gene signature consisting of functionally related nuclear genes with roles in DNA replication/ repair and/or
cell cycle that can improve accuracy of prognosis in
patients with PCa after RP in the context of current clinicopathological variables. Prognostic gene signatures containing, or based on, cell cycle gene expression changes
have been identified using other approaches and different
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sample types. This observation not only validates our results, but also suggests that heterogeneity may lead to
similar cellular consequences, providing cell cycle based
signatures with rather global prognostic values. The
TMCC11 signature requires further validation in
multi-institutional cohorts and clinical trials. In addition,
the ability of TMCC11 to provide prognostic information
using biopsy samples needs to be further explored.
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